Novalix 2025: Biophysics in Drug Discovery
About the talk
Dr. Andreas Frutiger, Head of R&D at lino Biotech AG, spoke at the 11th Novalix Biophysics in Drug Discovery Conference (June 2025). He presented how focal molography addresses the DEL hit validation bottleneck.
The DEL validation problem
The traditional DEL workflow requires off-DNA synthesis and characterization of every promising hit. This generates significant work in the chemistry department while producing limited biologically relevant information. The bottleneck scales poorly when a selection returns tens or hundreds of hits worth pursuing.
Focal molography's contribution
By exploiting the DNA tag for directed immobilization, focal molography enables direct on-DNA characterization. It delivers fast and label-free kinetic profiling of up to 54 DEL hits in a single instrument run, without the need for off-DNA synthesis. Kinetic parameters kon and koff are read directly from the on-DNA compound bound to the sensor surface.
About the speaker
Dr. Andreas Frutiger is Head of R&D at lino Biotech AG. He has co-authored the foundational publications on focal molography as a label-free biomolecular interaction analysis technology.
More videos and webinars
Discovery on Target 2026: From Living-Cell GPCRs to On-DNA DEL Hits
Dr. Volker Gatterdam
Market Development Manager·lino Biotech AG
Label-free kinetics on GPCRs in living cells and on-DNA validation of DEL hits, measured in crude matrices without purification. Recorded at Discovery on Target 2026 in Boston.
Development of an Fc-Capturing Protein for High-Throughput Screening at Miltenyi Biotec
Artem Siemens
Team Coordinator, Binder Discovery Group·Miltenyi Biotec
Recorded at the 3rd focal Molography User Meeting, Artem Siemens (Miltenyi Biotec) shows how a homodimeric capture nanobody, immobilized by DNA-directed immobilization (DDI), ...
Watch after a short form
Focal molography for the Fc receptor profiling of therapeutic anti-IgE antibodies
Dr. Paul Engeroff
University of Bern
A multiplex Fc receptor panel on focal molography maps where omalizumab, ligalizumab and their immune complexes with IgE and allergen bind, across all human Fc gamma and IgE ...
Watch after a short form